Den Europæiske Union - dansk - EMA (European Medicines Agency)

merck sharp & dohme b.v. - letermovir - cytomegalovirusinfektioner - antivirale midler til systemisk anvendelse - prevymis er indiceret til forebyggelse af cytomegalovirus (cmv) reaktivering og sygdom i voksen cmv-seropositive modtagere [r +] af en allogen hæmatopoietisk stamcelletransplantation (hsct). det bør overvejes at officielle vejledning om hensigtsmæssig brug af antivirale agenter.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mylan pharmaceuticals limited - acetylsalicylic acid, clopidogrel hydrogen sulfate - acute coronary syndrome; myocardial infarction - antitrombotiske midler - clopidogrel/acetylsalicylsyre mylan er angivet for den sekundære forebyggelse af atherothrombotic hændelser hos voksne patienter, som allerede tager både clopidogrel og acetylsalicylsyre (asa). clopidogrel/acetylsalicylsyre mylan er en fast dosis kombination lægemiddel til fortsættelse af terapi i:non-st-segment elevation akut koronar syndrom (ustabil angina pectoris eller non-q-tak myokardieinfarkt), herunder patienter, der gennemgår en stent placering efter perkutan koronar interventionst segment elevation akut myokardieinfarkt i medicinsk behandlede patienter, der er berettiget til trombolytisk terapi.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medical valley invest ab - clopidogrelbesilat - filmovertrukne tabletter - 75 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bayer ag - larotrectinib sulfat - abdominal neoplasmer - antineoplastiske midler - vitrakvi som monoterapi er indiceret til behandling af voksne og pædiatriske patienter med solide tumorer, hvor der vises en neurotrophic receptor tyrosin kinase (ntrk) gen fusion,der har en sygdom, der er lokalt avanceret, metastatisk eller hvor kirurgisk resektion er sandsynligvis resultere i alvorlig sygelighed, andwho har ingen tilfredsstillende behandling valg.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiske midler - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiske midler - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

eli lilly nederland b.v. - pirtobrutinib - lymfom, mantelcelle - protein kinase hæmmere - treatment of mantle cell lymphoma (mcl).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh - vismodegib - carcinom, basalcelle - antineoplastiske midler - erivedge er indiceret til behandling af voksne patienter med:- symptomatisk metastatisk basal celle karcinom - lokalt avanceret basal celle karcinom upassende for kirurgi eller strålebehandling.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi winthrop industrie - cabazitaxel - prostatiske neoplasmer - antineoplastiske midler - jevtana i kombination med prednison eller prednisolon er indiceret til behandling af patienter med hormon-ildfast metastatisk prostatacancer, der tidligere er behandlet med en docetaxelholdig behandling.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - olaparib - Æggestokkene neoplasmer - antineoplastiske midler - Æggestokkene cancerlynparza er angivet som monoterapi til:vedligeholdelse behandling af voksne patienter med avanceret (figo faser iii og iv) brca1/2-muterede (germline og/eller somatiske) high-grade epitelial ovariecancer, æggeleder eller primær peritoneal cancer, der er i reaktion (hel eller delvis) efter afslutningen af første linje platin-baseret kemoterapi. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 og 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. patienter bør have, der tidligere er blevet behandlet med en antracyklin og en taxane i (neo)adjuvans eller metastatisk indstilling, medmindre patienter, der ikke var egnet til disse behandlinger (se afsnit 5. patienter med hormon receptor (hr)-positiv brystkræft bør også have udviklet sig på eller efter forudgående endokrine terapi, eller anses uegnet til at endokrine terapi. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.